Results 61 to 70 of about 216,339 (397)

Bowel Perforation in the Emergency Department Related to Bevacizumab Therapy and Recurrent Ovarian Cancer [PDF]

, 2020
Case Presentation: We describe the presentation to the emergency department of a patient with recurrent ovarian cancer treated with bevacizumab with the complication of bowel perforation.
Burleson, Samuel L., Leath III, Charles A., Olushoga, Michael, Ostby, Stuart A.   +3 more
core  

Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy. [PDF]

, 2017
Anti-angiogenic therapies for cancer such as VEGF neutralizing antibody bevacizumab have limited durability. While mechanisms of resistance remain undefined, it is likely that acquired resistance to anti-angiogenic therapy will involve alterations of the
Aghi, MK, Castro, BA, Chen, W, De Lay, M, Flanigan, P, Hoffman, D, Jahangiri, A, Kohanbash, G, Kuang, R, Mascharak, S, Okada, H, Shrivastav, S, Sidorov, M, Wagner, JR, Yagnik, G   +14 more
core   +1 more source

Bevacizumab Increases Endothelin-1 Production via Forkhead Box Protein O1 in Human Glomerular Microvascular Endothelial Cells In Vitro

International Journal of Nephrology, 2021
Molecular mechanisms underlying the nephrotoxicity associated with bevacizumab are unclear. Endothelin-1 (ET-1) is involved in podocyte injury and proteinuria, and its level increases in most cases of kidney disorders.
Satoru Nihei, Junichi Asaka, Hiroaki Takahashi, Kenzo Kudo   +3 more
doaj   +1 more source

Metformin: a modulator of bevacizumab activity in cancer? A case report. [PDF]

, 2015
Recurrent type I endometrial cancer ((EC)) has poor prognosis and demands novel therapeutic approaches. Bevacizumab, a VEGF-A neutralizing monoclonal antibody, has shown clinical activity in this setting. To our knowledge, however, although some diabetic
Aliberti, C, Casarin, A, Indraccolo, Stefano, Nardin, M, Nicoletto, Mo, Pomerri, Fabio, Randon, G, Zulato, E   +7 more
core   +1 more source

Evaluation of the association between bevacizumab concentration and clinical outcomes in patients with breast cancer brain metastasis

Heliyon
Bevacizumab is widely used in various clinical indications, but investigations into its optimal dosage for treating CNS metastases remain limited. The BEEP regimen, comprising bevacizumab, etoposide, and cisplatin, has recently demonstrated promising ...
Chih-Ning Cheng, Yun-Jung Tsai, Huai-Hsuan Chiu, Tom Wei-Wu Chen, Ching-Hung Lin, Yen-Sheng Lu, Ching-Hua Kuo   +6 more
doaj   +1 more source

Multiparametric MRI and [18F]fluorodeoxyglucose positron emission tomography imaging is a potential prognostic imaging biomarker in recurrent glioblastoma [PDF]

, 2017
Purpose/objectivesMultiparametric advanced MR and [18F]fluorodeoxyglucose (FDG)-positron emission tomography (PET) imaging may be important biomarkers for prognosis as well for distinguishing recurrent glioblastoma multiforme (GBM) from treatment-related
Akash Sharma, Anupama Chundury, Christina I. Tsien, Comron Hassanzadeh, Comron Hassanzadeh, Jackson Rowe, Joseph E. Ippolito, Joseph E. Ippolito, Maria Rosana Ponisio, Michelle Miller-Thomas, Yuan James Rao   +10 more
core   +3 more sources

Intravenous Bevacizumab Therapy in a Patient with Hereditary Hemorrhagic Telangiectasia, ENG E137K, Alcoholic Cirrhosis, and Portal Hypertension

Case Reports in Gastroenterology, 2017
Intravenous bevacizumab decreased mucosal bleeding in some patients with hereditary hemorrhagic telangiectasia (HHT). We treated a 47-year-old male who had HHT, severe epistaxis, and gastrointestinal bleeding, alcoholic cirrhosis, and portal hypertension
Luigi F. Bertoli, Pauline L. Lee, Lauren Lallone, James C. Barton   +3 more
doaj   +1 more source

Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study

Liver Cancer, 2021
Introduction: Atezolizumab-bevacizumab is the new standard of care for first-line treatment of advanced hepatocellular carcinoma (HCC). However, the optimal sequence of therapy after disease progression on atezolizumab-bevacizumab is unclear.
C. Yoo, Jwa Hoon Kim, M. Ryu, Sook Ryun Park, Danbi Lee, K. Kim, J. Shim, Y. Lim, H. Lee, J. Lee, D. Tai, S. Chan, B. Ryoo   +12 more
semanticscholar   +1 more source

Adverse events associated with intraocular injection of anti-VEGF(bevacizumab) in retinal vein ccclusion: a case report [PDF]

, 2015
Introduction: Antiangiogenic agents are often administered for treatment of Branch Retinal Vein Occlusion (BRVO). Among them, Bevacizumab has noticeable antiangiogenic and antiedemigenic properties and possesses great capacity to penetrate the retinal ...
ARTICO, Marco, BOTTONE, Andrea, Domenica Piraino, Carmen, Mollicone, Antonella, PACELLA, Elena, PACELLA, FERNANDA, Romana Parisiella, Francesca, TURCHETTI, PAOLO   +7 more
core   +1 more source

Bleeding and thrombotic events in bevacizumab-treated patients with colorectal cancer on novel oral anticoagulants and antiplatelet medications

American Heart Journal Plus, 2023
Background: Bevacizumab is a humanized monoclonal anti-VEGF antibody often given in combination with fluorouracil-based chemotherapy as therapy for metastatic colorectal cancer (mCRC).
Shinji Rho, Chris Wang, Seyed Hamed Hosseini Dehkordi, James J. Sears, Z. Ian Hu   +4 more
doaj   +1 more source